Baker et al. suggested the use of a 4-gene score (AREG, EREG, DUSP6, SLC26A3) for the prediction of anti-EGFR treatment benefit in KRAS wild type CRC[28]. The gene discussed is DUSP6; the disease is colorectal carcinoma.